By PPN News Staff
The monoclonal antibody cocktail casirivimab and imdevimab (Regen-COV, Regeneron Pharmaceuticals) significantly reduced viral load within seven days of treatment in patients hospitalized with COVID-19, according to a presentation at IDWeek 2021, held virtually (abstract LB4).
In the phase 2/3, double-blind, placebo-controlled trial assessing casirivimab-imdevimab in 1,197 patients hospitalized with COVID-19, patients were randomly selected 1:1:1 to receive a one-time infusion of